{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:30:42Z","timestamp":1790854242762,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.coph.2007.06.001","type":"journal-article","created":{"date-parts":[[2007,7,13]],"date-time":"2007-07-13T07:45:21Z","timestamp":1184312721000},"page":"412-417","source":"Crossref","is-referenced-by-count":69,"title":["Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases"],"prefix":"10.1016","volume":"7","author":[{"given":"Richard O.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Paleolog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2007.06.001_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature03727","article-title":"Design of effective immunotherapy for human autoimmunity","volume":"435","author":"Feldmann","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.coph.2007.06.001_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2249.1993.tb03399.x","article-title":"Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma","volume":"92","author":"Williams","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib3","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.4049\/jimmunol.158.11.5507","article-title":"Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice","volume":"158","author":"Vermeire","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib4","unstructured":"Smolen J, van der Heijde D, Devogelaer J-P, Han C, Bala M, Baker D, Han J, St. Clair EW: The effect of infliximab therapy on the prevention of new erosions in patients with early rheumatoid arthritis. Arthritis Rheum 2004, 50 Suppl. 9:Abstract 357."},{"key":"10.1016\/j.coph.2007.06.001_bib5","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/art.1780390702","article-title":"Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis","volume":"39","author":"Tak","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2007.06.001_bib6_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L","article-title":"Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis","volume":"43","author":"Taylor","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2007.06.001_bib7","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/art.21544","article-title":"Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2007.06.001_bib9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1","article-title":"Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis","volume":"41","author":"Paleolog","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2007.06.001_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2007.06.001_bib11_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","article-title":"Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta","volume":"204","author":"Nadkarni","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2007.06.001_bib12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI117394","article-title":"Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor\/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis","volume":"94","author":"Cope","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2007.06.001_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/art.21491","article-title":"The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study","volume":"54","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2007.06.001_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/rheumatology\/36.6.643","article-title":"Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy","volume":"36","author":"Brennan","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.coph.2007.06.001_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/rheumatology\/41.5.484","article-title":"Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis","volume":"41","author":"Catrina","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coph.2007.06.001_bib16","first-page":"238","article-title":"Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis","volume":"31","author":"Klimiuk","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coph.2007.06.001_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0091270006298188","article-title":"Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis","volume":"47","author":"Zhou","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.coph.2007.06.001_bib18","unstructured":"Kay J, Matteson EL, Dasgupta N, Nash P, Durez P, Hall S, Hsia EC, Chiruvolu P, Han J, Rahman MU: One-year results of golimumab compared with placebo in patients with active RA despite treatment with methotrexate: a phase II, randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheumat 2006, 54 Suppl:Abstract 1075."},{"key":"10.1016\/j.coph.2007.06.001_bib19","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2007.06.001_bib20","doi-asserted-by":"crossref","unstructured":"Bingham CO, Genovese MC, Moreland LM, Grimes I, Parsey MV: Results of a phase II study of IL1-Trap in moderate to severe rheumatoid arthritis. Arthritis Rheumat 2004, 50 Suppl 9:Abstract 517.","DOI":"10.1002\/art.20221"},{"key":"10.1016\/j.coph.2007.06.001_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780390513","article-title":"Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice: a comparative study using anti-TNF\u03b1, anti-IL-1\u03b1\/\u03b2, and IL-1Ra","volume":"39","author":"Joosten","year":"1996","journal-title":"Arthritis Rheumat"},{"key":"10.1016\/j.coph.2007.06.001_bib22","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.4049\/jimmunol.165.12.7240","article-title":"Evaluation of TNF\u03b1 and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF\u03b1\/anti-CD4 therapy","volume":"165","author":"Williams","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheumat"},{"key":"10.1016\/j.coph.2007.06.001_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2249.2001.01487.x","article-title":"Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys","volume":"124","author":"Brok","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib25","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheumat"},{"key":"10.1016\/j.coph.2007.06.001_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.coph.2004.03.005","article-title":"Inhibition of IL-6 for the treatment of inflammatory diseases","volume":"4","author":"Nishimoto","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.coph.2007.06.001_bib27","unstructured":"McInnes I, Martin R, Zimmerman-Gorska I, Nayiager S, Sun G, Patel A, Appleton B: Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): results from a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumat. 2004, 50 Suppl 9:Abstract 527."},{"key":"10.1016\/j.coph.2007.06.001_bib28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.coph.2004.04.003","article-title":"Interleukin-15: a new cytokine target for the treatment of inflammatory diseases","volume":"4","author":"McInnes","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.coph.2007.06.001_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.ibd.0000225337.14356.31","article-title":"A phase 1\/2A trial of STA 5326, an oral interleukin-12\/23 inhibitor, in patients with active moderate to severe Crohn's disease","volume":"12","author":"Burakoff","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2007.06.001_bib30","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2007.06.001_bib31","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.0022-202X.2004.23448.x","article-title":"A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis","volume":"123","author":"Kauffman","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2007.06.001_bib32","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1172\/JCI115814","article-title":"Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis","volume":"89","author":"Weyand","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2007.06.001_bib33","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1073\/pnas.0308231100","article-title":"T cell receptor zeta reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor alpha","volume":"101","author":"Clark","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2007.06.001_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00002281-200305000-00013","article-title":"The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis","volume":"15","author":"Weyand","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.coph.2007.06.001_bib35","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1073\/pnas.91.7.2762","article-title":"Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis","volume":"91","author":"Williams","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2007.06.001_bib36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2007.06.001_bib37_1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.coph.2007.06.001_bib38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 Family Cytokines and the Expanding Diversity of Effector T Cell Lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2007.06.001_bib41","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2007.06.001_bib42","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.4049\/jimmunol.167.2.1004","article-title":"IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis","volume":"167","author":"Lubberts","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib43","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.171.11.6173","article-title":"Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice","volume":"171","author":"Nakae","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib44","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2007.06.001_bib45_1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.coph.2007.06.001_bib46","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2007.06.001_bib47","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20061099","article-title":"Interleukin-23 drives innate and T cell-mediated intestinal inflammation","volume":"203","author":"Hue","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2007.06.001_bib48","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl. 3","key":"10.1016\/j.coph.2007.06.001_bib49","doi-asserted-by":"crossref","first-page":"iii34","DOI":"10.1136\/ard.2006.058412","article-title":"The BLyS\/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity","volume":"65","author":"Cancro","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2007.06.001_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2007.04.008","article-title":"B cells and the BAFF\/APRIL axis: fast-forward on autoimmunity and signaling","author":"Mackay","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib51","first-page":"12","article-title":"Updates from B Cell Trials: Efficacy","volume":"77","author":"Cohen","year":"2006","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.coph.2007.06.001_bib52_1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.coph.2007.06.001_bib53","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2007.06.001_bib54","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/art.20965","article-title":"Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine","volume":"52","author":"Ikeuchi","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2007.06.001_bib55","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.4049\/jimmunol.178.9.5973","article-title":"IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease","volume":"178","author":"Wolk","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2007.06.001_bib56","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/labinvest.3780127","article-title":"Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis","volume":"80","author":"Miotla","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.coph.2007.06.001_bib57","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.gt.3302104","article-title":"Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis","volume":"10","author":"Afuwape","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.coph.2007.06.001_bib58","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1538-7836.2003.00263.x","article-title":"Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders","volume":"1","author":"Autiero","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coph.2007.06.001_bib59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00441-003-0776-3","article-title":"VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis","volume":"314","author":"Tjwa","year":"2003","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.coph.2007.06.001_bib60","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","article-title":"Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1","volume":"9","author":"Autiero","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2007.06.001_bib61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/88842","article-title":"Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration","volume":"28","author":"Oosthuyse","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.coph.2007.06.001_bib62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1365-2249.2000.01097.x","article-title":"Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid","volume":"119","author":"Bottomley","year":"2000","journal-title":"Clin Exp Immunol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489207001014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489207001014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T02:14:38Z","timestamp":1737252878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489207001014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S1471489207001014"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2007.06.001","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}